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Simple Summary: Activated or apoptotic platelets both shed platelet microparticles that are proven
to be internalized by many different cell types, including cancer cells. Here, we have investigated
whether platelet microparticles can transfer their contents to the monocytic leukemia cell line THP-
1 and if this could change cell activity and resistance to chemotherapy. We show that platelet
microparticles were internalized by THP-1 cells and that platelet-associated microRNAs were elevated
after a brief co-incubation. Furthermore, differentiation toward macrophages was induced and
cell cycle progression, proliferation, and mitochondrial activity were decreased. Co-incubation
with platelet microparticles increased chemotherapy resistance, which also was evident in acute
myelogenous leukemia cells from patient samples, and it could be explained by the decrease in
cell activity. Thus, platelet microparticles may have a role in the evolution of acute myelogenous
leukemia and contribute to development of chemotherapy resistance, making them an interesting
target for treatment.
Abstract: The role of platelets in cancer development and progression is increasingly evident, and
several platelet–cancer interactions have been discovered, including the uptake of platelet micropar-
ticles (PMPs) by cancer cells. PMPs inherit a myriad of proteins and small RNAs from the parental
platelets, which in turn can be transferred to cancer cells following internalization. However, the
exact effect this may have in acute myelogenous leukemia (AML) is unknown. In this study, we
sought to investigate whether PMPs could transfer their contents to the THP-1 cell line and if this
could change the biological behavior of the recipient cells. Using acridine orange stained PMPs,
we demonstrated that PMPs were internalized by THP-1 cells, which resulted in increased levels
of miR-125a, miR-125b, and miR-199. In addition, co-incubation with PMPs protected THP-1 and
primary AML cells against daunorubicin-induced cell death. We also showed that PMPs impaired
cell growth, partially inhibited cell cycle progression, decreased mitochondrial membrane potential,
and induced differentiation toward macrophages in THP-1 cells. Our results suggest that this altering
of cell phenotype, in combination with decrease in cell activity may offer resistance to daunorubicin-
induced apoptosis, as serum starvation also yielded a lower frequency of dead and apoptotic cells
when treated with daunorubicin.
Keywords: acute myelogenous leukemia; platelets; microparticles; apoptosis
1. Introduction
Acute myelogenous leukemia (AML) is a bone marrow malignancy originating in
hematopoietic stem and progenitor cells [1–3]. The average 5-year survival rate for de novo
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disease is approximately 50% in younger patients [4], but this may vary widely depending
on the occurrence of a selection of genetic aberrances. According to the 2017 European
LeukemiaNet genetic risk stratification of AML, survival varies from 20% to over 60% [5].
Curative treatment involves intensive chemotherapy and, for select high-risk patient
groups, the addition of consolidating treatment with allogenic stem cell transplantation,
which carries the risk of a fatal outcome [6]. Thus, there is a need for a better understanding
of tumorigenesis and evolution of the disease to improve treatment strategies.
Platelet–cancer interactions are becoming increasingly evident, and there is proof of
cancer disease fundamentally altering the platelet transcriptome [7]. In aggregates with
cancer cells, platelet function is hijacked to evade the NK cell response [8,9] and induce
cancer cell epithelial–mesenchymal transition to facilitate metastasis [10,11]. Platelets
are also important mediators for the development and maintenance of the cancer cell
microenvironment [12,13].
Platelet microparticles (PMPs) are small membranous platelet particles (<1000 nm),
which either bud off as a result of platelet activation [14] or as apoptotic bodies [15,16].
These microparticles are internalized by a variety of cell types, transferring their contents
during this process [16–19]. PMPs contain a selection of the myriad of parent platelet alpha
granule proteins [20,21] and platelet-associated microRNAs [22,23], which may potentially
affect the biological behavior of the cells that have internalized them. This transfer of
microRNAs has been demonstrated in a number of cancer models [24–26], where, although
the effects are dependent on the cancer type and model, the PMPs appear to have both pro
and anti-tumoral properties.
Targeting anti-apoptotic proteins is a novel strategy in the treatment of AML [27].
BCL2 is an important regulator of the intrinsic or mitochondrial apoptosis pathway, inhibit-
ing BCL2 Antagonist/Killer (BAK) and BCL2 Associated X, Apoptosis Regulator (BAX)
oligomerization, thus preventing pore formation in the outer mitochondrial membrane and
subsequently leading to the leakage of cytochrome c and activation of caspase-9 [28]. Both
platelet releasate and lysate seem to counter the effects of agents that specifically target
this pathway, revealing an anti-apoptotic potential of platelets in AML [29]. There is also
evidence that intrinsic apoptosis can be affected by the transfection of certain microRNAs,
which are also found to be overexpressed in AML and present in platelets, indicating the
potential relevance of these regulatory RNA molecules in an interaction between AML
cells and platelets [30,31].
The role of microRNAs in AML is further supported by several studies showing
an association of microRNA expression with mortality and chemotherapy resistance in
patients, in whom several of the microRNAs are known to be present in high concentrations
in platelets and platelet microparticles [32–34]. In this study, we aimed to assess whether
PMPs could be taken up by AML cells and if this would change the AML cells’ microRNA
levels and in vitro chemotherapy resistance.
2. Results
2.1. Platelet-Associated microRNAs Are Increased in THP-1 Cells after PMP Co-Incubation
To examine whether platelet microparticles could be internalized by AML cells, we
cultured cells from the monocytic AML cell line THP-1, with acridine orange (AO)-stained
PMPs for 18 h. There was a PMP concentration-dependent increase of fluorescence in the
co-incubated cells, and fluorescence microscopy revealed that that the stain was indeed
dispersed within the cell nucleus and not located to bound microparticles (Figure 1A,B).
To further investigate whether this PMP internalization could increase microRNA levels,
we analyzed a selection of platelet-associated microRNAs in THP-1 cells after 18 h of
co-incubation with PMPs. miR-125a-5p, miR-125b-5p, and miR-199-5p levels were all
markedly increased (Figure 1C). This was particularly true for miR-199-5p, where levels
were undetectable without PMP co-incubation in 2/3 samples (range 37.55–not detected),
versus an average Cq value of 33.20 (range 33.13–33.24) with PMP co-incubation. These
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findings give indirect proof that microRNAs can be transferred from platelets to THP-1
cells through PMP internalization.
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2.2. PMPs Lead to Increased Resistance of THP-1 Cells to DNR
Both miR-125a-5p and miR-125b-5p have been associated with resistance to chemother-
apy in retroviral transduction studies [30,31]. Therefore, we examined whether the cytotoxic
effect of daunorubicin (DNR), a common front-line chemotherapeutic in AML, could be
influenced by PMP internalization. Co-incubation of THP-1 cells with PMPs decreased
the relative frequency of dead and apoptotic cells in a concentration-dependent manner
following treatment with DNR (Figure 2A). Thus, for all other analyses, PMPs were co-
incubated at a concentration of 1.5 × 107 per mL medium, unless otherwise specified, as
this generated the highest chemoprotective effect. Vector control experiments, where the
supernatant of isolated PMPs was added to Iscove’s Modified Dulbecco’s Medium (IMDM)
+ 10% FBS medium at a concentration of 5%, only had a small and non-significant effect on
resistance to DNR (p = 0.109).
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Figure 2. Apoptosis and cell death in THP-1 and primary acute myelogenous leukemia (AML) cells
treated with 0.5 µM daunorubicin. (A) Difference in frequency of dead and apoptotic cells in THP-1
cells with or without co-incubation with platelet microparticles (PMPs) (n = 3). Number following
different PMP groups denotes final concentration in million PMPs per mL medium. (B) Evaluation
of the effect of PMPs on the frequency of dead and apoptotic cells in primary AML cells (nine patient
samples, n = 4). p values were calculated using the one-sample t test (test value = 0). * p < 0.05.
2.3. Co-Incubation of Primary AML Cells with PMPs Also Increased Resistance to DNR
As there are limitations for the clinical relevance of cell line AML models [35], we
examined whether the chemoprotective effect of PMPs could be observed in cells derived
from AML patients. Using a similar approach, albeit with serum-free conditions, our results
showed an identical effect on primary AML cells where we identified a significantly lower
frequency of dead and apoptotic cells when PMPs were added (Figure 2B). The average
absolute reduction in dead and apoptotic cells in individual patient samples ranged from
0.2 to 55.9% and was significant in 8/9 patients (Figure S1). One-way ANOVA analysis of
the effects on THP-1 cells of PMPs from different releasates (when used in the primary AML
experiments as quality controls) revealed no significant inter-releasate batch difference
(p = 0.823).
2.4. THP-1 Cells Co-Incubated with PMPs Had Lower Caspase-9 Activity Following
DNR-Treatment
Using microRNA databases (miRDB [36] and TargetScanHuman [37]), we fou d
several predicted target mRNAs for miR-125a-5p and miR-125b-5p with important roles
in the intrinsic apoptotic pathway, such as the pro-apoptotic BCL2 family proteins, BCL2
Modifying Factor (BMF) and BAK1 [38]. To investigate whether PMP internalization
could influence the intrinsic apoptotic pathway, THP-1 cells were co-incubated with PMPs
and treated with DNR using the established approach. Then, the cells were analyzed
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for caspase-9 activation, which is a downstream effect of mitochondrial outer membrane
permeabilization (MOMP). There was a lower frequency of caspase-9 positive cells in the
THP-1 cell cultures co-incubated with PMPs (Figure 3), suggesting that the chemoprotective
effect of PMPs could be the result of the effects on the intrinsic apoptotic pathway upstream
of caspase-9 activation.
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Figure 3. Caspase-9 activation in daunorubicin ( R)-induced cell death. DNR-treated THP-1 cells ere analyzed for
caspase-9 activation (n = 3). Caspase-9 positive cells w re identified as the distinct second peak in the flow histogram.
p values w re calculated using the paired-sample t test. * p < 0.05.
2.5. Decreased Cell Activity Protected THP-1 Cells against R
Cytotoxic chemotherapy is believed to be ost potent in highly proliferating cancer
cells. Inducing cellular dormancy to decrease DNA replication should theoretically offer
a chemoprotective effect, as it would prevent DNR-triggered DNA d mage. Thus, we
investigated w ther serum st rvation would decrease cell activity and subsequently
protect THP-1 cells against DNR. We analyzed proliferation, ell cycle distribution, and
mit chondrial embrane potential, and we observed that 48 h of serum starvation in
THP-1 cells induced a significant growth arrest (Figure 4A–C). To evaluate whether serum
starvation affected DNR-resistance, we compared a optosis and cell death in THP-1 ce ls,
ith or ithout serum starvation, 24 h after treatment with 0.5 µ D R. e s o ed a
marked reduction in the frequency of dea an a o totic cells ( i r ).
To i estigate hether the arent c e oprotective effect f -i ation
may be the result of a similar d cr ase in cell activity, we m asured the ef ects of PMPs
on cell proliferation, cell cycle distribution, and mitochondrial m mbra e potential. Our
results s owed that co-i cubation with PMPs increased the frequency of cells in the G0/G1
cell phase, reduced mitochondrial membra e potential, and inhibited cell proliferation
(Figure 5A–C). These findings lead us to believe that PMPs may protect THP-1 cells from
DNR-induced cell death by partially inhibiting cell cycle progression and proliferation.
Co-incubation with PMPs did not alter mRNA or protein levels of CDK4 (Figure 5D,E),
which is fundamental for THP-1 viability and normal cell cycle progression [39,40].
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compar d to sta dard conditions. (A–C) w re compared using th paired-sample t e t. (D) was c mpared using the
one-s mple t test (test value = 0). * p < 0.05.
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Figure 5. Effects of platelet microparticles (PMPs) on cell activity in THP-1 cells. (A) Proliferation analysis by Cell Trace
Figure 5. (n = 5). (B) Cell cycle analysis (n = 3). Cells in G0/G1 cell phase were gated. (C) Mitochondrial membrane
potential (n = 4), mean fluorescence intensity (MFI) data. (D) CDK4 mRNA levels (n = 3). (E) CDK4 protein levels (n = 5).
(B–E) were analyzed after 24 h of PMP co-incubation. mRNA data are calculated as fold change from THP-1 without
PMP co-incubation, normalized for ACTB. Protein data are calculated as fold change in MFI from THP-1 without PMP
co-incubation. Data were compared using the paired-sample t test for data pairs or the one-sample Wilcoxon signed-rank
test for ratios. * p < 0.05. ** p < 0.001.
2.6. o-I c batio I creased ifferentiation of THP-1 Cells toward acrophages
-1 cells are ca a le f acr a e iffere tiati , lea i t cell r t arrest.
Th s, e ante to exa ine if increased differentiation of the cells could contribute
to the observed decrease in cell cycle progression. PMP co-incubation increased both
forward scatter and side scatter (Figure 6A), indicating increased cell size and granularity,
which are two hallmarks of macrophage differentiation [41]. Surprisingly, we could not
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corroborate the forward scatter findings with measurement of cell cross-sectional area
using the particle analysis function in the ImageJ software with pictures taken under an
inverted phase-contrast microscope (Figure 6B). However, co-incubation with PMPs led
to a significant increase in CD14 antigen expression (Figure 6C). Thus, the decrease in
cell cycle progression, and therefore part of the chemoprotective effect, could stem from
differentiation of the cells toward macrophages.
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3. Discussion
The important role of platelets in cancer development, progression, and metastasis
is becoming increasingly clear, and there are several known mechanisms in this interplay,
including the transfer and uptake of platelet microparticles. We showed that co-incubating
primary AML cells and THP-1 cells with PMPs increased their DNR resistance. In ad-
dition we demonstrated the inhibition of THP-1 cell proliferation, cell cycle progression,
mitochondrial membrane potential, and induction of differentiation toward macrophages.
We observed internalization of PMPs by THP-1 cells and a subsequent increase of
platelet-associated microRNAs. The internalization was observed using AO-stained PMPs.
AO will stain DNA, RNA, and acidic vesicles. Platelets do not contain DNA, other than a
small amount of mtDNA. However, platelets and PMPs both contain RNA and lysozomes,
making AO staining suitable for our purpose.
Co-incubation of THP-1 or primary AML cells with PMPs increased their resistance
to DNR-treatment at a concentration of 0.5 µM, which is close to the peak plasma concen-
tration measured in patients receiving 60 mg/m2 DNR [42]. In AML, DNR is routinely
administrated at dosages of 45–90 mg/m2 [43]. This observed chemoprotective effect could
be the result of microRNA transfer from PMPs. The overexpression of both miR-125a
and miR-125b have been associated with DNR resistance in AML cell lines, including
THP-1 [30,31]. Using the transduction of THP-1 cells with murine stem cell virus (MSCV),
these studies obtained a 4 and 4.9-fold increase of miR-125a and miR-125b. In our study,
the respective levels were increased 3.0 and 3.2-fold. The transduction of miR-125a and
miR-125b resulted in downregulation of the apoptotic proteins Grk2 and Puma [30,31].
The latter is a member of the pro-apoptotic BH3-only proteins of the intrinsic apoptosis
pathway [38], where we show a decrease in activation with PMP co-incubation. These
proteins are known to be crucial participants in apoptosis, as genetic knockout models
are protected against several apoptotic stimuli [44]. However, the cited studies with the
transduction of miR-125a and miR-125b did not include an analysis of cell activity in the
THP-1 cells associated with microRNA overexpression, which may be decisive for the
actual DNA-damage induced by DNR. Other studies have linked the ectopic expression of
miR-125a with proliferation inhibition, although in solid tumor cell lines [45,46].
PMPs contain several hundred different proteins and small RNAs, meaning the
underlying mechanism for chemoprotection are likely more complex than that reflected
in the single microRNA transduction studies. The anti-cancer effect of DNR and other
anthracyclines are believed to mainly be a result of interference with topoisomerase II (Top2)
enzyme activity [47]; however, other mechanisms have been identified [48]. Top2 introduces
double-strand DNA breaks during replication [47]; thus, an inhibition of proliferation
should decrease the efficiency of Top2 poisons. We showed that decrease of cell activity
through serum starvation protects THP-1 cells against DNR-triggered apoptosis and cell
death, and we suggest that PMPs could offer chemoprotection through this mechanism.
Vasina and colleagues have previously shown that microparticles from apoptotic platelets
can induce macrophage differentiation in THP-1 cells after 7 days of co-incubation [16]. Here,
we show prominent upregulation of CD14 antigen already after 48 h using platelet mi-
croparticles from activated platelets from platelet concentrates containing a mixture of
PMPs generated by activation and apoptosis, better resembling the in vivo milieu. Seem-
ingly, there are conflicting results regarding cell size analyses, as forward scatter and side
scatter were increased, but the measured cross-sectional cell area was unchanged. However,
we believe the increase in light scatter was affected by morphological changes with more
vacuolization in the cells treated with PMPs.
The observed differentiation effect can at least partially explain the decrease in cell
cycle progression, as THP-1 cells treated with phorbol myristate acetate for macrophage
differentiation only exit G1 phase to a little extent [49]. CDK4 mRNA and protein levels
were unchanged, and the decrease in cell cycle progression would appear to be the result of
a downstream target. However, notable downregulation of the CDK4 gene is known to be
a later event in macrophage differentiation of THP-1 cells [49]. We have not identified the
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exact substances that initiate differentiation or lead to the inhibition of cell cycle progression.
The latter could partially be an independent process, because contrary to our findings,
mitochondrial activity is increased with macrophage differentiation [41]. Transforming
growth factor beta (TGF-β) is a potent cell cycle regulator known to be present in platelets.
TGF-β induces dormancy or quiescence through several mechanisms, but it cannot be
entirely responsible for the observed chemoprotective effect of PMPs, as it is known to be
abundant in the platelet secretome [50,51], and we did not observe any significant effects
on the frequency of dead and apoptotic cells in our vector control experiments.
Several research groups have reported that PMPs affect cancer development. Michael
and colleagues showed that PMPs could infiltrate solid tumors and inhibit the growth of
lung and colon cancer [26]. Others have linked PMPs to increased epithelial–mesenchymal
transition and metastatic capacity in ovarian cancer [25] and lung cancer invasion [24].
Recent evidence has shown that platelets can have a bimodal effect in colorectal cancer
where they inhibit growth but promote metastasis [52]. An extensive review of the role of
PMPs in cancer progression can be found elsewhere [53].
Our protocol for the quantitation of microparticles has some limitations, as the PMP
number per mL releasate varied on average by 10.0%, but it ranged from 0.4 to 34.9%
between technical replicates. Thus, the final concentration of PMPs in the culture media may
have varied extensively in some experiments. Accordingly, the concentration of microRNAs
and proteins will vary from batch to batch of platelet concentrates. We accounted for the
latter when we chose to use pooled platelet concentrates derived from four different donors.
Furthermore, we found no inter-batch differences with respect to chemoprotective effect.
The induction of resistance to DNR by PMPs could have significant clinical relevance.
Inhibiting the production of PMPs may present a potential therapeutic approach in AML to
increase chemosensitivity. This can easily be achieved with platelet inhibition [54]. Platelet
inhibition has also previously been linked to both lower cancer incidence and improved
cancer-specific survival [55–58], although the exact mechanism is unknown. On the flip
side, the differentiation of AML cells by PMPs might be beneficial to inhibit evolution of
the disease.
4. Materials and Methods
4.1. Cell Line
The THP-1 cell line was purchased from ATCC (American Type Culture Collection;
Manassas, VA, USA) and maintained in Iscove’s Modified Dulbecco’s Medium (IMDM;
Thermo Fisher Scientific, Waltham, MA, USA) + 10% FBS (Sigma Aldrich, St. Louis, MO,
USA). Only cells in the exponential growth phase were used, and cultures were kept for
less than three months.
4.2. Primary AML Cells
Primary AML cells were isolated by density gradient separation of peripheral blood
from consenting patients at the Department of Medicine, Section of Hematology, Haukeland
University Hospital (Bergen, Norway). The cells were cryopreserved in liquid nitrogen until
use. The cryopreservation solution consisted of insulin-free RPMI 1640 (Sigma Aldrich),
supplemented with 10% dimethylsulfoxide and 20% FBS. Primary AML cells were cultured
in StemSpan Serum-Free Expansion Medium (Stem Cell Technologies, Vancouver, BC,
Canada) with the addition of the following recombinant cytokines in a final concentration
of 20 ng/mL: stem cell factor (Peprotech EC, London, UK), G-CSF (Peprotech), and FMS-
like tyrosine kinase 3 ligand (Peprotech). Charateristics of the AML patients can be found
in Table 1.
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FAB Cytogenetics FLT3 NPM1 CEBPA CD11b CD14 CD33 CD34 CD45 CD64 CD117 HLA-DR
L-
MPO




wt neg neg pos pos dim pos pos dim
2 F 60 PV del(7) wt wt wt neg neg pos dim pos pos
3 F 56 No M4 inv(16) wt wt neg neg pos pos dim neg pos pos pos
4 M 44 No M4 inv(16) wt wt neg neg neg neg dim dim neg pos
5 F 92 No M1 neg neg dim neg dim dim pos pos pos
6 M 49 No M4 45, XY wt ins wt neg neg neg dim dim pos pos
7 M 76 No M5 Normal wt ins wt hetero hetero neg hetero pos hetero pos
8 F 95 No M4 Normal wt wt wt dim dim dim




wt wt neg neg neg pos dim neg neg pos pos
# patient number.
4.3. Platelet Concentrate
Routinely prepared platelet concentrates pooled from four donors (Tacsi system;
Terumo BCT, Lakewood, CO, USA) were provided by the Department of Immunology
and Transfusion Medicine, Stavanger University Hospital (Stavanger, Norway), after
written consent from the donors. The platelet concentrations were 0.88–1.08 × 109 per
mL. Leukocytes were removed by filtration to a residual level of <1.00 × 106. In the final
concentrate, the storage medium contained approximately 65% additive solution (PAS-III,
Baxter, Lake Zurich, IL, USA) and 35% plasma.
4.4. Platelet Releasate
The platelet concentrate was transferred from the blood bag to separate 50 mL tubes
and incubated with a final concentration of 1 U/mL human thrombin (Sigma Aldrich) for
one hour in a 37 ◦C water bath. The tubes were gently agitated every 5 min. The platelet
releasate was centrifuged for 10 min at 900× g, and the supernatant was transferred to new
50 mL tubes. The samples were stored at −80 ◦C. Fibrin clots that appeared after thawing
were plucked using a 10 mL serological pipette.
4.5. Platelet Microparticles Isolation, Co-Culture, and Measurement
Platelet releasate was centrifuged at 15,000× g for 90 min at room temperature and
the supernatant was carefully poured off. To examine the biological effects of platelet
microparticles, a mastermix of StemSpan + cytokines (for primary cells), or IMDM + 10%
FBS (for THP-1 cells), was used to resuspend PMPs before transfer to cell culture and
thoroughly mixed with the cells by pipetting. Two hours after the PMPs were added to the
cell cultures, the wells were mixed again by pipetting. For quantitation, the microparticles
were resuspended in 400 µL of 0.22 µm filtered Annexin V Binding Buffer (Miltenyi Biotec,
Bergisch Gladbach, Germany), before 200 µL of the solution was transferred to a second
tube. Twenty µL of Annexin V FITC (Milteny Biotec), and 2 µL of anti-CD61 APC (clone
Y2/51; Miltenyi Biotec), or 22 µL of 0.22 µm filtered Annexin V Binding Buffer for an
unstained control, were added and incubated for 15 min at room temperature. Finally,
278 µL of 0.22 µm filtered Annexin V Binding Buffer and 50 µL CountBright beads (Thermo
Fisher Scientific) were added before analysis. Microparticle gates were set with Megamix-
PLUS FSC beads (size range of beads: 0.3 to 0.9 µm; BioCytex, Marseille, France) using the
side scatter channel, according to Poncelet and colleagues [59]. At least 2500 bead events
were collected. This as well as all other flow cytometric analyses were performed on a
CytoFLEX flow cytometer (Beckman Coulter, Brea, CA, USA) using CytExpert ver. 2.4
acquisition and analysis software (Beckman Coulter).
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4.6. Acridine Orange Staining of Platelet Microparticles
Platelet releasate was stained with 100 µg/mL of acridine orange (Thermo Fisher
Scientific) and incubated for 30 min at room temperature. Then, the solution was washed
and centrifuged two times at 15,000× g for 90 min. Tubes were changed after the first wash
step to avoid any contamination of acridine orange that may have adhered to the plastic.
Finally, the PMPs were resuspended in IMDM + 10% FBS and co-cultured with THP-1 cells
for 18 h at a concentration of 5 × 106 PMPs per mL. The cells were harvested and washed
twice in Dulbecco’s phosphate-buffered saline (DPBS; Sigma Aldrich) before analysis with
flow cytometry using the FITC channel, and with a Zeiss Axioplan 2ie MOT fluorescence
microscope (Carl Zeiss, Göttingen, Germany) using an SpGreen filter. At least 25,000 gated
cells were collected for flow cytometric analysis.
4.7. mRNA and microRNA Analysis
Total RNA was isolated using the miRNeasy kit (QIAGEN GmbH, Hilden, Germany),
and RNA concentration was measured on a NanoDrop 2000 spectrophotometer (Thermo
Fisher Scientific). Reverse transcription was performed with the TaqMan MicroRNA Re-
verse Transcription Kit (Thermo Fisher Scientific), and the High-Capacity cDNA Reverse
Transcription Kit (Thermo Fisher Scientific). Real-Time PCR was done on the Mx3005P
qPCR system (Agilent Technologies, Palo Alto, CA, USA) using TaqMan MicroRNA Assays
(Thermo Fisher Scientific) with the TaqMan Universal Master Mix for microRNA analy-
ses (Thermo Fisher Scientific), and the TaqMan gene expression assays (Thermo Fisher
Scientific) with the TaqMan Gene Expression Master Mix (Thermo Fisher Scientific) for
mRNA analyses, following the manufacturer’s instructions. BCR or ACTB were used
as reference genes, and the relative expression was calculated using the 2−∆∆Cq method.
∆∆Cq was calculated as ∆Cq value (target gene minus reference gene) for cells without
PMP co-incubation minus ∆Cq value for PMP co-incubated cells. For a comprehensive list
of the microRNA and mRNA assays used in this study, see Table S1.
4.8. Daunorubicin Apoptosis Assay
Approximately 5 × 105 cells per mL of resuscitated primary AML cells, or THP-1
cells in exponential growth phase, were cultured under aforementioned conditions with or
without PMPs for 24 h. The cells were then treated with 0.5 µM daunorubicin hydrochloride
(Sigma Aldrich) for another 24 h before further analysis. THP-1 cells were also used as
a quality control for the experiments with primary AML cells. Then they were kept in
the same batch of StemSpan + cytokines to detect any false negative results in case of
issues with the PMP isolation. Cell viability was analyzed with the Annexin V-FITC kit
(Miltenyi Biotec), strictly following the manufacturer’s instructions. Dead and apoptotic
cells were analyzed using flow cytometry and gated out in a single gate using a pseudo
color plot of FITC-A versus PerCP Cy 5.5-A after doublet discrimination. For analysis with
primary AML cells, contaminating cells were gated out based on light scatter properties.
See Figure S2 for gating strategies. At least 25,000 gated cells were collected.
4.9. Caspase-9 Activity
Caspase-9 activity in daunorubicin-treated THP-1 cells was measured using the Casp-
GLOW Fluorescein Active Caspase-9 Staining Kit (Thermo Fisher Scientific). Approxi-
mately 5 × 105 cells in 0.3 mL IMDM + 10% FBS were stained with 1 µL FITC-LEHD-FMK
and incubated for 30 min in a CO2 incubator before washing twice with the supplied wash
medium and analysis with flow cytometry. Both untreated and treated, but not stained
THP-1 cells, were used as negative controls. At least 25,000 gated cells were collected.
4.10. Mitochondrial Membrane Potential
Mitochondrial membrane potential was assessed using the MitoProbe DiIC1(5) Assay
Kit (Thermo Fisher Scientific). THP-1 cells were cultured with or without PMPs for 24 h
before 5 × 105 cells in 1 mL IMDM + 10% FBS were stained with DiIC1(5) using carbonyl
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cyanide 3-chlorophenylhydrazone-treated cells as a correction for background signal and
incubated for 30 min following the manufacturer’s instructions. After doublet discrimi-
nation, MFI (mean fluorescence intensity) values of gated cells were compared using the
APC channel on the flow cytometer. See Figure S3A and B for gating strategy. At least
30,000 gated cells were collected.
4.11. Cell Cycle Analysis
THP-1 cells were incubated for 24 h in IMDM + 10% FBS with or without PMPs. Cells
were washed and 5 × 105 cells were stained with 10 µM Vybrant Dye Cycle Green Stain
(Thermo Fisher Scientific) and incubated for 30 min in a 37 ◦C water bath. Immediately
after incubation, the cells were analyzed using the FITC channel on the flow cytometer.
2N cells, representing G0/G1 cell phase, were gated out after doublet discrimination. See
Figure S3A and C for gating strategy. At least 10,000 gated cells were collected.
4.12. Flow Cytometry Proliferation Analysis
Proliferation analysis was performed with the Cell Trace Far Red Proliferation Kit
(Thermo Fisher Scientific) and analyzed with the APC channel on the flow cytometer. On
day 0, THP-1 cells at a concentration of 1 × 106 per mL were stained with 5 µM Far Red
reagent in DPBS and incubated briefly for 5 min in a 37 ◦C water bath to avoid excessive cell
toxicity. The stained cells were washed with IMDM + 20% FBS and cultured as previously
described. Medium with or without PMPs was added on days 2 and 4 to keep concentration
of cells below 8 × 105 per mL. A sample of the cells was analyzed on day 0 to identify
baseline MFI. At least 25,000 gated cells were collected.
4.13. Flow Cytometry Immunophenotyping
THP-1 cells were cultured under aforementioned conditions with or without PMP
co-incubation and harvested after 48 h. Approximately 1 × 106 cells were washed in DPBS,
resuspended in 98 µL of DPBS containing 0.5% BSA, and labeled with 2 µL of anti-CD14
APC (clone REA599; Miltenyi Biotec). The cells were incubated for 10 min at 4 ◦C and
washed before analysis. An unstained sample was used to determine background signal.
At least 30,000 gated cells were collected.
4.14. Measurement of CDK4 by Indirect Intracellular Flow Cytomtery
THP-1 cells were cultured for 24 h before harvest and analyzed for intracellular
protein using the published protocol by Ludwig and colleagues [60]. Briefly, cells were
fixed and permeabilized using the eBioscience Foxp3/Transcription Factor Staining Buffer
Set (Thermo Fisher Scientific). Then, cells were incubated with unconjugated anti-CDK4
(clone DCS-31; Thermo Fisher Scientific) and labeled with the proper conjugated secondary
antibody. Dilution and incubation time can be found in Table S2. A “no primary antibody”
sample was used to subtract background signal. At least 25,000 gated cells were collected.
4.15. Measurement of Cell Cross-Sectional Area
For measurement of the cross-sectional area, cultured cells were transferred to a Bürker
chamber to minimize the physical cell membrane manipulation and assessed under an
inverted phase-contrast microscope. Four representative fields per technical replicate at
100× magnification were captured using an Olympus Pen Lite E-PL5 camera (Olympus,
Tokyo, Japan). Pictures were analyzed using the particle analysis function of the ImageJ
software ver. 1.52k [61]. Image optimization and thresholding was performed as described
in the Supplementary Methods.
4.16. Serum Starvation
In separate experiments, analysis of daunorubicin-induced apoptosis and cell death,
cell cycle, and mitochondrial membrane potential were performed in serum-starved THP-1
cells without PMP co-incubation. Cells in the exponential growth phase were washed,
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resuspended, and kept for 48 h in IMDM before further analysis, as described in the
separate sections. For measurement of proliferation rate, cells were resuspended at a
concentration of 4 × 105 per mL IMDM, with or without 10% FBS, and counted using the
flow cytometer after 24, 48, and 72 h.
4.17. Statistical Analysis
Statistical analyses were performed using the IBM SPSS 26 software (IBM Corp.,
Armonk, NY, USA). Comparison between experimental groups was performed using tests
for paired or independent data when appropriate. The data were checked for normality
using P-P plots, Shapiro–Wilks test, and Kolmogorov–Smirnov test. A p value < 0.05 was
considered significant. Mean values are reported with a 95% confidence interval unless
otherwise specified. “n” denotes technical replicates.
5. Conclusions
We show that PMP co-incubation decreases mitochondrial membrane potential, in-
hibits cell cycle progression, decreases proliferation, and induces differentiation toward
macrophages in THP-1 cells. This differentiation effect, combined with decrease in cell
activity, may explain the observed protection against daunorubicin-induced cell death,
which is also evident in primary AML cells.
Our results warrant further research to explore the in vivo effects of platelet micropar-
ticles in AML, both as anti-apoptotic agents, and as modulators of the disease, as they
represent possible therapeutic targets through the use of platelet inhibitors.
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